The production linked incentive scheme (PLI) for pharmaceutical products has export generation potential of Rs 1,96,000 crore over a period of six years, Parliament was informed on Tuesday.
The government had approved the PLI scheme for pharmaceuticals on February 24 this year.
"The scheme estimated the export generation potential of Rs 1,96,000 crore over a period of six years in all the three categories of products under the scheme, which includes high-value products as well," Chemicals and Fertilisers Minister Mansukh Mandaviya said in a written reply to the Lok Sabha.
The PLI scheme estimated the investment potential of around Rs 15,000 crore and the generation of the employment potential of 20,000 direct and 80,000 indirect jobs as a result of the growth in the sector over the period of the scheme, he added.
The minister noted that currently, low-value generic drugs account for the major component of Indian exports.
The scheme incentivises the manufacturing of patented drugs and other high-value drugs at an incentive rate of 10 per cent of incremental sales, which is the highest among the product categories under the scheme, he added.
On June 1 this year, the government had issued operational guidelines for the PLI scheme for the pharmaceutical industry to enhance India's manufacturing capabilities by increasing investment and production in the sector.
Earlier, the Department of Pharmaceuticals had notified the scheme with an outlay of Rs 15,000 crore.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)